Ingen oplysninger underbygger, at dosis- bivirkningskurven (myopati, hepatotoksicitet) skulle være stejlere for rosuvastatin end for andre statiner.
There are no data to support a steeper dose relationship for adverse reactions (myopathy, hepatotoxicity) for rosuvastatin, compared with other statins.